SUN vs BEV þIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

British Journal of Cancer (2010) 102, 232–233. doi:10.1038/sj.bjc.6605446 www.bjcancer.com& 2010 Cancer Research UKSir,It is with great interest that I read the article by Thompson Coonet al, as I agree with the authors that there is a need for performingindirect treatment comparisons in order to offer guidance ontherapy decisions to oncologists.As this is an important topic, I would like to outline some methodo-logical issues that are related to the Thompson Coon et al analysis.